{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:30:08Z","timestamp":1759797008721,"version":"build-2065373602"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ijrobp.2022.09.079","type":"journal-article","created":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T11:20:29Z","timestamp":1664796029000},"page":"608-621","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Emerging Role of Immunomonitoring to Predict the Clinical Outcome of Patients With Malignant Pleural Mesothelioma Treated With Radical Radiation Therapy"],"prefix":"10.1016","volume":"115","author":[{"given":"Michela","family":"Cangemi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcella","family":"Montico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Trovo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Minatel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Di Gregorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Corona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiana","family":"Giordari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Comaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Colizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena","family":"Babo\u00e7i","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agostino","family":"Steffan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Revelant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Muraro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2022.09.079_bib0001","doi-asserted-by":"crossref","first-page":"234","DOI":"10.21037\/atm.2017.03.74","article-title":"Environmental asbestos exposure and risk of mesothelioma","volume":"5","author":"Noonan","year":"2017","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0002","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0003","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1136\/oemed-2019-105779","article-title":"Role of asbestos clearance in explaining long-term risk of pleural and peritoneal cancer: A pooled analysis of cohort studies","volume":"76","author":"Barone-Adesi","year":"2019","journal-title":"Occup Environ Med"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0004","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1136\/thoraxjnl-2013-204161","article-title":"Mesothelioma risk after 40 years since first exposure to asbestos: A pooled analysis","volume":"69","author":"Reid","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0005","first-page":"244","article-title":"Epidemiology of malignant pleural mesothelioma in the province of Sassari (Sardinia, Italy). A population-based report","volume":"85","author":"Budroni","year":"2014","journal-title":"Ann Ital Chir"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0006","first-page":"S397","article-title":"Malignant pleural mesothelioma: Current and future perspectives","volume":"5","author":"Porpodis","year":"2013","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0007","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1111\/crj.12778","article-title":"Global trends in mortality from malignant mesothelioma: Analysis of WHO mortality database (1994-2013)","volume":"12","author":"Abdel-Rahman","year":"2018","journal-title":"Clin Respir J"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.554570","article-title":"Epigenetic alterations and biomarkers for immune checkpoint inhibitors-current standards and future perspectives in malignant pleural mesothelioma treatment","volume":"10","author":"Yoshikawa","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0009","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3390\/ijerph15051000","article-title":"Global asbestos disaster","volume":"15","author":"Furuya","year":"2018","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0010","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3390\/ijerph17020607","article-title":"Predictions of mortality from pleural mesothelioma in Italy after the ban of asbestos use","volume":"17","author":"Oddone","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0011","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/LCTT.S102113","article-title":"Clinical staging of malignant pleural mesothelioma: Current perspectives","volume":"8","author":"Bonomi","year":"2017","journal-title":"Lung Cancer Targets Ther"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0012","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.21037\/tlcr.2020.01.08","article-title":"Surgery for pleural mesothelioma, when it is indicated and why: Arguments against surgery for malignant pleural mesothelioma","volume":"9","author":"Woodard","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0013","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3389\/fonc.2019.01519","article-title":"Malignant pleural mesothelioma: State-of-the-art on current therapies and promises for the future","volume":"9","author":"Nicolini","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0014","doi-asserted-by":"crossref","first-page":"F1000","DOI":"10.12688\/f1000research.15796.1","article-title":"Multimodality treatment of malignant pleural mesothelioma","volume":"7","author":"Berzenji","year":"2018","journal-title":"F1000Res"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0015","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.lungcan.2014.01.021","article-title":"Surgery for malignant pleural mesothelioma: Why, when and what?","volume":"84","author":"Lang-Lazdunski","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0016","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.7587","article-title":"A clinical-based risk score for decision making for surgery after induction chemotherapy in malignant pleural mesothelioma patients","volume":"31","author":"Opitz","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0017","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomized, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0018","doi-asserted-by":"crossref","first-page":"12468","DOI":"10.18632\/oncotarget.3487","article-title":"Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model","volume":"6","author":"Wu","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0019","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.3390\/cancers12102762","article-title":"Radiotherapy-mediated immunomodulation and anti-tumor abscopal effect combining immune checkpoint blockade","volume":"12","author":"Zhao","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40364-021-00264-1","article-title":"Anti-mesothelin CAR T cell therapy for malignant mesothelioma","volume":"9","author":"Castelletti","year":"2021","journal-title":"Biomark Res"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0021","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/S1470-2045(15)00208-9","article-title":"Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17\/04): A randomised, international, multicentre phase 2 trial","volume":"16","author":"Stahel","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0022","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/1754-9485.12636","article-title":"High-dose palliative radiotherapy for malignant pleural mesothelioma","volume":"61","author":"Foroudi","year":"2017","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0023","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ijrobp.2015.06.029","article-title":"Radical radiation therapy after lung-sparing surgery for malignant pleural mesothelioma: Survival, pattern of failure, and prognostic factors","volume":"93","author":"Minatel","year":"2015","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0024","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/1759-7714.12860","article-title":"Intensity-modulated radiotherapy is a safe and effective treatment for localized malignant pleural mesothelioma","volume":"9","author":"Simon","year":"2018","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0025","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1016\/S1470-2045(17)30459-X","article-title":"Radiotherapy for the treatment of malignant pleural mesothelioma","volume":"18","author":"de Perrot","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0026","doi-asserted-by":"crossref","first-page":"212","DOI":"10.21037\/tlcr.2017.04.01","article-title":"Immunotherapy and radiation therapy for malignant pleural mesothelioma","volume":"6","author":"Alley","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0027","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jnci\/djs629","article-title":"Combining radiotherapy and cancer immunotherapy: A paradigm shift","volume":"105","author":"Formenti","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0028","doi-asserted-by":"crossref","first-page":"e92572","DOI":"10.1371\/journal.pone.0092572","article-title":"Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model","volume":"9","author":"Yoshimoto","year":"2014","journal-title":"PloS ONE"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0029","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.3390\/ijms20133212","article-title":"Tumor microenvironment as a \u201cgame changer\u201d in cancer radiotherapy","volume":"20","author":"Jarosz-Biej","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0030","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.3389\/fimmu.2017.01476","article-title":"Local high-dose radiotherapy induces systemic immunomodulating effects of potential therapeutic relevance in oligometastatic breast cancer","volume":"8","author":"Muraro","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0031","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.ijrobp.2020.11.057","article-title":"Radical Hemithoracic Radiotherapy Versus Palliative Radiotherapy in Non-metastatic Malignant Pleural Mesothelioma: Results from a Phase 3 Randomized Clinical Trial","volume":"109","author":"Trovo","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0032","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0033","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12885-018-4136-9","article-title":"Effect of surgery and radiotherapy on complete blood count, lymphocyte subsets and inflammatory response in patients with advanced oral cancer","volume":"18","author":"Dov\u0161ak","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0034","first-page":"121","article-title":"Radiation sensitivity of human and murine peripheral blood lymphocytes, stem and progenitor cells","volume":"1846","author":"Heylmann","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0035","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/jrr\/rraa083","article-title":"Changes in peripheral immune cells after intraoperative radiation therapy in low-risk breast cancer","volume":"62","author":"Linares-Galiana","year":"2021","journal-title":"J Radiat Res (Tokyo)"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0036","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.hbpd.2020.12.015","article-title":"The effects of stereotactic body radiotherapy on peripheral natural killer and CD3+CD56+ NKT-like cells in patients with hepatocellular carcinoma","volume":"20","author":"Li","year":"2021","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0037","article-title":"Changes in T lymphocyte subsets in different tumors before and after radiotherapy: A meta-analysis","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0038","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.lungcan.2020.09.026","article-title":"Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients","volume":"150","author":"Fusco","year":"2020","journal-title":"Lung Cancer Amst Neth"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0039","doi-asserted-by":"crossref","first-page":"12295","DOI":"10.3390\/ijms222212295","article-title":"Bridging radiotherapy to immunotherapy: The IFN-JAK-STAT axis","volume":"22","author":"Shi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0040","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/eji.201646723","article-title":"IL-17 and IL-22 in immunity: Driving protection and pathology","volume":"47","author":"Eyerich","year":"2017","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103180","article-title":"Immune system in cancer radiotherapy: Resistance mechanisms and therapy perspectives","volume":"157","author":"Mortezaee","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0042","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nature14191","article-title":"Necroptosis and its role in inflammation","volume":"517","author":"Pasparakis","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0043","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.radonc.2010.09.002","article-title":"Pathogenetic mechanisms in radiation fibrosis","volume":"97","author":"Yarnold","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0044","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1515\/CCLM.2010.165","article-title":"Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population","volume":"48","author":"Park","year":"2010","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0045","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1158\/1078-0432.CCR-10-1929","article-title":"Serum soluble mesothelin concentrations in malignant pleural mesothelioma: Relationship to tumor volume, clinical stage and changes in tumor burden","volume":"17","author":"Creaney","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0046","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ijrobp.2021.05.014","article-title":"Regulatory T cells shape the differential impact of radiation dose-fractionation schedules on host innate and adaptive antitumor immune defenses","volume":"111","author":"Sia","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0047","doi-asserted-by":"crossref","first-page":"eabd9882","DOI":"10.1126\/scitranslmed.abd9882","article-title":"Triple-modality therapy maximizes antitumor immune responses in a mouse model of mesothelioma","volume":"13","author":"Murakami","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0048","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): A multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0049","doi-asserted-by":"crossref","first-page":"5725","DOI":"10.3390\/cancers13225725","article-title":"Changes in blood biomarkers of angiogenesis and immune modulation after radiation therapy and their association with outcomes in thoracic malignancies","volume":"13","author":"Gkika","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ijrobp.2022.09.079_bib0050","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ccr.2011.11.003","article-title":"IL-10 elicits IFN\u03b3-dependent tumor immune surveillance","volume":"20","author":"Mumm","year":"2011","journal-title":"Cancer Cell"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301622034149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301622034149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T10:04:41Z","timestamp":1759745081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301622034149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0360301622034149"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2022.09.079","relation":{},"ISSN":["0360-3016"],"issn-type":[{"type":"print","value":"0360-3016"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Role of Immunomonitoring to Predict the Clinical Outcome of Patients With Malignant Pleural Mesothelioma Treated With Radical Radiation Therapy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2022.09.079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}